First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study

Abstract Adding a PD-1/PD-L1 inhibitor to gemcitabine plus cisplatin (GemCis) has shown survival benefits in advanced biliary tract cancer (BTC). Dual inhibition of PD-1/PD-L1 and TIGIT may act synergistically, and further enhance antitumor effects. ZSAB-TOP was a single-arm, multicenter, phase 2 st...

Full description

Saved in:
Bibliographic Details
Main Authors: Guoming Shi, Xiaoyong Huang, Liang Ma, Hui Li, Jianhong Zhong, Junye Wang, Qiang Gao, Xiaojun Guo, Shuangjian Qiu, Huichuan Sun, Yinghong Shi, Xiaowu Huang, Xiaoying Wang, Yong Yi, Xiaodong Zhu, Cheng Huang, Zhenbin Ding, Yi Chen, Yifeng He, Yinghao Shen, Qiman Sun, Jian Zhou, Jia Fan
Format: Article
Language:English
Published: Nature Publishing Group 2025-08-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-025-02356-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41392-025-02356-y

Similar Items